title: [Is it ethical conducting placebo-controlled clinical trials as part of the development of new drugs for the treatment of major depressive disorder? (and II). Benefit/risk ratio and informed consent. Conclusions].
authors.affiliation: Departamento Médico, GlaxoSmithKline S.A. Tres Cantos, Madrid, Spain. jld23465@gsk.com
authors.forename: Juan
authors.initials: J
authors.lastname: Lahuerta
authors.forename: Diego
authors.initials: D
authors.lastname: Gracia
authors.forename: Miquel
authors.initials: M
authors.lastname: Casas
authors.forename: Enrique
authors.initials: E
authors.lastname: Baca
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use*; D018849:Controlled Clinical Trials as Topic / Q000941:ethics*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D030881:Disclosure; D006801:Humans; D007258:Informed Consent; D010919:Placebos; D018570:Risk Assessment
chemical_list: D000928:Antidepressive Agents; D010919:Placebos